Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 9/20 | 0.43 |
| ▸ | CTSS | P25774 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195367 | 1.00 | HDAC4 (0.47) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL861489 | 1.00 | HDAC4 (0.47) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL4214930 | 1.00 | HDAC4 (0.47) | HDAC4HDAC1HDAC6CTSKCTSS | |
| Hydrochloric Acid SCHEMBL16007751 | 0.88 | HDAC4 (0.46) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL500438 | 0.85 | HDAC4 (0.44) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL3687446 | 0.85 | HDAC4 (0.44) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL861583 | 0.85 | HDAC4 (0.44) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL24190473 | 0.84 | HDAC4 (0.41) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL3725538 | 0.82 | CTSS (0.50) | HDAC4HDAC1HDAC6CTSKCTSS | |
| SCHEMBL742779 | 0.82 | CTSS (0.50) | HDAC4HDAC1HDAC6CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183413-B2 | Process for production of β-amino-α-hydroxy carboxamide derivative | KANEKA CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| US-20090312577-A1 | Process for Production of Beta-Amino-Alpha-Hydroxy Carbonxamide Derivative | KANEKA CORPORATION (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1988073-A1 | PROCESS FOR PRODUCTION OF BETA-AMINO-ALPHA-HYDROXY ACID AMIDE DERIVATIVE | Kaneka Corporation (JP) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312577-A1 | Process for Production of Beta-Amino-Alpha-Hydroxy Carbonxamide Derivative | PTMA, ATIC, HCAR2 | HDAC4 1731/4885HDAC1 1980/4885HDAC6 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.